Loading...
Nuvation Bio Inc.
NUVB-WT•NYSE
HealthcareBiotechnology
$0.27
$0.05(22.67%)
Nuvation Bio Inc. (NUVB-WT) Stock Overview
Explore Nuvation Bio Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for NUVB-WTStats details for NUVB-WT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NUVB-WTAnalyst Recommendations details for NUVB-WT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Employees
220
Headquarters
New York City, DE
Founded
1970